Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Go back to Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)| (NASDAQ: OCGN) | Delayed: 1.07 +0.01 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.06 | 52 Week High | $ | |||
| Open | $1.07 | 52 Week Low | $ | |||
| Day High | $1.07 | P/E | N/A | |||
| Day Low | $1.07 | EPS | $ | |||
| Volume | 5,528 | |||||
